Dr Dumbrava is a Medical Oncologist and Assistant Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and Director for MD Anderson Cancer Network Research for Investigational Cancer Therapeutics/Phase 1. Dr Dumbrava completed her medical oncology training at Gustave Roussy Cancer Center in Villejuif, France, followed by a Master of Science Degree from Paris-South University and a postdoctoral fellowship in the Department of Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. She completed two years of Clinical Fellowship in the Investigational Cancer Therapeutics Department, where she was elected Chief Fellow and during which she did a clinical research rotation at NCI/CTEP. She joined the Department of Investigational Cancer Therapeutics since August 2018 as an Assistant Professor. She is also member of the Brain Metastasis Clinic. Dr Dumbrava was the FY19 K12 Paul Calabresi Scholar Award and FY21 Gateway Foundation for Cancer Research Award recipient. Dr Dumbrava is overseeing the Inpatient Service and leading the HER2 Working Group in the Investigational Cancer Therapeutics Department at The University of Texas MD Anderson Cancer Center and she also an active member in the Immunotherapy and Cellular Therapies Working Group. Her main area of research lies in targeting p53 and HER2 and developing cellular therapies for solid tumors and genomically matched combination therapies and personalized immunotherapy clinical trials.

Dr Andrew Furness is Consultant Medical Oncologist based at the Royal Marsden Hospital. He treats patients with cancers of the skin and kidney and leads clinical research in solid tumour cellular therapy in a pan tumour manner. He is a Team Leader and Clinical Lead of the Centre for Translational Immunotherapy at the Institute of Cancer Research, where his research interests lie in translational immunology and cell-based immunotherapy. He leads the Solid Tumour Cellular Therapy subgroup of the British Society of Bone Marrow Transplantation and Cellular Therapy, acts as faculty member of the European Society for Medical Oncology Tumour Immunology and Immunotherapy and Investigational Immunotherapy groups. He is motivated to expand the reach of immunotherapy to a greater fraction of patients with solid tumours and hopes to achieve this through cell-based approaches and a better understanding of the biology underlying response and resistance to existing approaches.